P3 Health Partners Inc Trading Halted Due to Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
P3 Health Partners Inc trading halted, volatility trading pause
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PIII?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PIII
Wall Street analysts forecast PIII stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 13.200
Low
8.00
Averages
14.00
High
20.00
Current: 13.200
Low
8.00
Averages
14.00
High
20.00
About PIII
P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
P3 Health Partners Reports Strong Q1 2026 Earnings and Raises Outlook
- Strong Financial Performance: P3 Health Partners reported $26 million in adjusted EBITDA for Q1 2026, exceeding internal expectations, which reflects the company's success in contract restructuring and market optimization, thereby enhancing confidence in its full-year outlook.
- Strategic Market Adjustments: CEO Aric Coffman emphasized a 15% year-over-year improvement in Medicare Advantage funding rates, with 63% of membership experiencing delegated functions, indicating a strategic shift in prioritizing markets and payer relationships.
- Revenue and Cost Control: Q1 revenue reached $386 million, up from $373 million in Q1 2025, despite a decline in membership to approximately 106,000, reflecting deliberate portfolio adjustments under economic thresholds.
- Optimistic Outlook: CFO Leif Pedersen revised the 2026 adjusted EBITDA outlook to a range of $20 million to $60 million, highlighting that this change reflects favorable prior year developments and payer settlements, showcasing the company's confidence in its operational trajectory moving forward.
See More
P3 Health Partners Q1 Earnings Beat Expectations
- Earnings Beat: P3 Health Partners reported a Q1 GAAP EPS of $0.32, surpassing expectations by $3.60, indicating strong profitability despite revenue falling short of forecasts.
- Slow Revenue Growth: The company generated $386 million in revenue for Q1, reflecting a 3.4% year-over-year increase, yet it missed analyst expectations by $5.5 million, which could undermine investor confidence in future growth.
- Market Reaction Analysis: While the earnings beat may initially support stock performance, the revenue miss could lead to volatility, prompting investors to closely monitor the company's strategic adjustments and market performance for long-term investment assessments.
- Future Outlook: The company must implement strategies to enhance revenue growth to meet market competition and investor expectations, ensuring a more comprehensive performance improvement in upcoming earnings reports.
See More
P3 Health Partners Q4 Earnings Report Analysis
- Earnings Performance: P3 Health Partners reported a Q4 GAAP EPS of -$23.02, missing expectations by $13.56, indicating ongoing challenges in profitability that may negatively impact investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $384.8M, a staggering 1153.4% increase year-over-year, exceeding expectations by $27.15M, demonstrating strong market demand despite a slight decline from last year's $1.50B total revenue.
- Medical Margin Improvement: The medical margin stood at $23.5M, or $17 PMPM, with normalized medical margin at $53.4M, reflecting progress in cost control and service efficiency, although the net loss reached $323.1M.
- Future Guidance: For 2026, adjusted EBITDA is expected to range from -$20M to $40M, with a midpoint of $10M, indicating a projected year-over-year improvement of approximately $170M, showcasing management's confidence in future profitability.
See More
P3 Health Partners Inc. Projects Total Revenue Between $1.5 Billion and $1.7 Billion for 2026
- Revenue Guidance: Health Partners Inc. has provided a total revenue guidance range for 2026, estimating between $1.5 billion and $1.7 billion.
See More
P3 Health Partners Reports Results for Fourth Quarter and Full Year 2025
Fourth Quarter Results: Health Partners has announced its results for the fourth quarter of 2025, highlighting key financial and operational metrics.
Full Year Performance: The organization also provided a comprehensive overview of its performance for the entire year of 2025, showcasing growth and achievements.
See More
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
P3 Health Partners Reports Strong Q1 2026 Earnings and Raises Outlook
- Strong Financial Performance: P3 Health Partners reported $26 million in adjusted EBITDA for Q1 2026, exceeding internal expectations, which reflects the company's success in contract restructuring and market optimization, thereby enhancing confidence in its full-year outlook.
- Strategic Market Adjustments: CEO Aric Coffman emphasized a 15% year-over-year improvement in Medicare Advantage funding rates, with 63% of membership experiencing delegated functions, indicating a strategic shift in prioritizing markets and payer relationships.
- Revenue and Cost Control: Q1 revenue reached $386 million, up from $373 million in Q1 2025, despite a decline in membership to approximately 106,000, reflecting deliberate portfolio adjustments under economic thresholds.
- Optimistic Outlook: CFO Leif Pedersen revised the 2026 adjusted EBITDA outlook to a range of $20 million to $60 million, highlighting that this change reflects favorable prior year developments and payer settlements, showcasing the company's confidence in its operational trajectory moving forward.
See More
P3 Health Partners Q1 Earnings Beat Expectations
- Earnings Beat: P3 Health Partners reported a Q1 GAAP EPS of $0.32, surpassing expectations by $3.60, indicating strong profitability despite revenue falling short of forecasts.
- Slow Revenue Growth: The company generated $386 million in revenue for Q1, reflecting a 3.4% year-over-year increase, yet it missed analyst expectations by $5.5 million, which could undermine investor confidence in future growth.
- Market Reaction Analysis: While the earnings beat may initially support stock performance, the revenue miss could lead to volatility, prompting investors to closely monitor the company's strategic adjustments and market performance for long-term investment assessments.
- Future Outlook: The company must implement strategies to enhance revenue growth to meet market competition and investor expectations, ensuring a more comprehensive performance improvement in upcoming earnings reports.
See More
P3 Health Partners Q4 Earnings Report Analysis
- Earnings Performance: P3 Health Partners reported a Q4 GAAP EPS of -$23.02, missing expectations by $13.56, indicating ongoing challenges in profitability that may negatively impact investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $384.8M, a staggering 1153.4% increase year-over-year, exceeding expectations by $27.15M, demonstrating strong market demand despite a slight decline from last year's $1.50B total revenue.
- Medical Margin Improvement: The medical margin stood at $23.5M, or $17 PMPM, with normalized medical margin at $53.4M, reflecting progress in cost control and service efficiency, although the net loss reached $323.1M.
- Future Guidance: For 2026, adjusted EBITDA is expected to range from -$20M to $40M, with a midpoint of $10M, indicating a projected year-over-year improvement of approximately $170M, showcasing management's confidence in future profitability.
See More
P3 Health Partners Inc. Projects Total Revenue Between $1.5 Billion and $1.7 Billion for 2026
- Revenue Guidance: Health Partners Inc. has provided a total revenue guidance range for 2026, estimating between $1.5 billion and $1.7 billion.
See More
P3 Health Partners Reports Results for Fourth Quarter and Full Year 2025
Fourth Quarter Results: Health Partners has announced its results for the fourth quarter of 2025, highlighting key financial and operational metrics.
Full Year Performance: The organization also provided a comprehensive overview of its performance for the entire year of 2025, showcasing growth and achievements.
See More
